-transparent.png){kind=logo}
Alacepril is a new angiotensin-converting enzyme (ACE) inhibitor that possesses sympatho-inhibitory action. We evaluated the effect of alacepril on blood pressure and progression of diabetic nephropathy in hypertensive type II diabetics in an open multicenter trial. Eighty-nine type II diabetics with mild hypertension were treated with 50 mg of alacepril daily and observed for 12 weeks. Blood pressure was reduced significantly at 4 weeks; this reduction continued throughout the study. Urinary excretion of albumin also was reduced significantly at 12 weeks. Glycosylated hemoglobin (HbA1c) and serum total cholesterol showed significant reduction with alacepril. We confirmed the beneficial effect of alacepril on blood pressure and diabetic nephropathy, and found that glucose and lipid metabolism improves in the diabetic state with this ACE inhibitor.
K Utsunomiya, and
Y Ikeda
March 1999,
Hypertension research : official journal of the Japanese Society of Hypertension,
K Utsunomiya, and
Y Ikeda
January 2004,
Redox report : communications in free radical research,
K Utsunomiya, and
Y Ikeda
September 2016,
Journal of veterinary cardiology : the official journal of the European Society of Veterinary Cardiology,
K Utsunomiya, and
Y Ikeda
January 1986,
Arzneimittel-Forschung,
K Utsunomiya, and
Y Ikeda
December 1997,
Methods and findings in experimental and clinical pharmacology,
K Utsunomiya, and
Y Ikeda
April 1989,
Angiology,
K Utsunomiya, and
Y Ikeda
January 1990,
General pharmacology,
K Utsunomiya, and
Y Ikeda
October 1985,
Clinical pharmacology and therapeutics,
K Utsunomiya, and
Y Ikeda
January 1990,
Clinical therapeutics,
K Utsunomiya, and
Y Ikeda
March 2003,
Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego,
